Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.59 - $1.44 $4,301 - $10,499
-7,291 Reduced 35.02%
13,531 $16,000
Q2 2022

Aug 15, 2022

BUY
$0.51 - $1.17 $10,619 - $24,361
20,822 New
20,822 $12,000
Q4 2019

Feb 18, 2020

SELL
$4.23 - $8.29 $63,027 - $123,520
-14,900 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$2.15 - $6.28 $30,100 - $87,920
-14,000 Reduced 48.44%
14,900 $70,000
Q2 2019

Aug 14, 2019

SELL
$2.49 - $3.73 $277,137 - $415,149
-111,300 Reduced 79.39%
28,900 $78,000
Q1 2019

May 15, 2019

SELL
$1.88 - $3.35 $13,160 - $23,450
-7,000 Reduced 4.76%
140,200 $393,000
Q4 2018

Feb 14, 2019

SELL
$1.66 - $4.16 $65,072 - $163,072
-39,200 Reduced 21.03%
147,200 $263,000
Q3 2018

Nov 14, 2018

BUY
$3.75 - $4.65 $198,000 - $245,520
52,800 Added 39.52%
186,400 $811,000
Q2 2018

Aug 14, 2018

BUY
$3.7 - $5.8 $494,320 - $774,880
133,600 New
133,600 $494,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $799M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.